Declaration of competing interest Louis J. Aronnereports receiving grants or personal fees from Altimmune, Amgen, Atria, Boehringer-Ingelheim, Carmot Therapeutics / Roche, CinFina Pharma, Corteria, Currax Pharma, Eli Lilly and Company, Enterin, Helicore Biopharma, Jamieson Wellness, Juvena Therapeutics, Kallyope, MBX Bioscience, Metsera, Novo Nordisk, Pfizer, Prosciento, Senda Biosciences, Skye Bio, Syntis Bio, Verdiva, Veru Pharmaceuticals and Zealand Pharmaceuticals; receiving institutional research funding from Eli Lilly, Novo Nordisk, Skye Bioscience and Viking Therapeutics; having equity interests in Clic Bio, ERX Pharmaceuticals, Flyte Health, Jamieson Wellness, Juvena Therapeutics, Kallyope, MBX Bioscience, Mediflix, Metsera, Skye Bio, Syntis Bio, Verdiva and Veru Pharmaceuticals; and serving on a board of directors for ERX Pharmaceuticals, Flyte Health and Jamieson Wellness. Deborah B. Horn has acted as a consultant, advisory board member, and speaker for Eli Lilly and Company and Novo Nordisk; has acted as an advisory board member for Amgen AstraZeneca, Boehringer Ingelheim, and Zealand; and has received institutional research funding from Eli Lilly and Company, KVK Tech, Novo Nordisk, and Weight Watchers. Alexander D. Kokkinosreports receiving grants from ELPEN Pharma, Novo Nordisk, and Pharmaserve Lilly, serving on advisory boards for Boehringer-Ingelheim, Novo Nordisk, Pharmaserve Lilly, and Sanofi, and receiving honoraria for lectures from AstraZeneca, Bausch Health, Epsilon Health, Ethicon, Galenica Pharma, MSD, Novo Nordisk, Pharmaserve Lilly, Sanofi, and Viatris. Beverly L. Falcon, Hunter T. Hoffmann, Clare J. Lee, and Julia P. Dunn are employees and shareholders of Eli Lilly and Company. Hui Wang was an employee of TechData Service Company and was contracted by Eli Lilly and Company for this study.
PubMed
